【摘要】：目的談?dòng)懩殠чg充質(zhì)干細(xì)胞(umbilical cord-mesenchymal stem cells,UCMSCs)治療異基因造血干細(xì)胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)后兒童急性移植物抗宿主病(acute graft versus host disease,a GVHD)及出血性膀胱炎(hemorrhagic cystitis,HC)的療效及安全性。方法異基因造血干細(xì)胞移植后發(fā)生難治性a GVHD及HC兒童共15例,其中a GVHD13例(Ⅰ度a GVHD 2例,Ⅲ度a GVHD 8例,Ⅳ度a GVHD 5例)、HC 5例(Ⅲ度4例,Ⅳ度1例)。在常規(guī)治療效果不佳的基礎(chǔ)上,聯(lián)合靜脈輸注UCMSCs。UCMSCs的平均使用劑量為3.6(1.25~6.0)×106,平均使用次數(shù)為5次(2~21次)。然后觀察a GVHD及HC的恢復(fù)、再發(fā)情況及輸注后不良反應(yīng)。結(jié)果allo-HSCT后發(fā)生a GVHD的全部13例患兒在對(duì)一線免疫抑制劑及CD25單抗治療無(wú)效,聯(lián)合UCMSCs治療后,8例獲得完全緩解,5例獲得部分緩解;5例HC患兒經(jīng)水化、堿化治療后效果欠佳,聯(lián)合靜脈輸注UCMSCs后癥狀緩解。本研究未觀察到UCMSCs輸注相關(guān)的不良反應(yīng)。結(jié)論聯(lián)合UCMSCs治療異基因造血干細(xì)胞移植后兒童a GVHD及HC安全有效。
[Abstract]:Objective to discuss the effect of umbilical cord mesenchymal stem cells (umbilical cord-mesenchymal stem cells,UCMSCs) on acute graft versus host disease (acute graft versus host disease,) in children after allogeneic hematopoietic stem cell transplantation (allogeneic hematopoietic stem cell transplantation,allo-HSCT). Efficacy and safety of a GVHD) and hemorrhagic cystitis (hemorrhagic cystitis,HC). Methods Fifteen children with refractory a-GVHD and HC after allogeneic hematopoietic stem cell transplantation (HSCT), including a-GVHD13 in 2 cases, a-GVHD in 8 cases, and), HC in 5 cases in grade 鈪，

本文編號(hào)：2455935